Statement from Beverly Winikoff, Gynuity President, on New Mifepristone Label

“The good news is that the approved regimen has finally caught up with medical practice and evidence. The bad news is mifepristone remains overly regulated and is still not available in pharmacies. While these changes will help many women, additional regulatory changes are essential to maximize access to this important medication. Mifepristone holds untapped potential for improving the availability and affordability of abortion in the U.S.”

-Beverly Winikoff, M.D., M.P.H., President, Gynuity Health Projects